Inhalation Sciences to conduct 1 MSEK CRO study for major European pharma company

Report this content

Inhalation Sciences (ISAB) is conducting a Contract Research Order feasibility study worth 1 MSEK for a leading European inhaled pharmaceutical developer. ISAB was chosen because of its unique ability to deliver predictive, voluminous data from tiny amounts of challenging substance in nebulized as well as dry powder aerosol.

“Few tests are more crucial in an inhaled drug’s lifetime than pre-clinical feasibility studies” says ISAB CEO Lena Heffler. “With a typical drug costing on average 2.6 BUSD to develop, being able to minimize errors and generate predictive data early on saves huge costs. And means faster drug development. The choice of PreciseInhale confirms its unique capabilities. We know the client faced challenges with this material earlier on. Our ability to generate predictive data even from tiny amounts of challenging substance only available in solution was key. We’re delighted they chose our system.”

PreciseInhale aerosol generating system generates accurate ex vivo and in vivo data from nebulized solutions as well as all major types of commercial dry powder inhaler. ISAB launched its new nebulizer feature in February 2019. The feasibility study is the first large-scale commercial study to use it. “Our tailored nebulizer feature plus our ability to handle challenging substances with high levels of excipient both show the kind of quality and capability that make us first choice for inhaled pre-clinical pharmaceutical R&D” says Heffler.

Work on the Feasibility Study began in June 2019 and is expected to run until October 2019.

For more information on Inhalation Sciences, please contact:

Lena Heffler, CEO 
Telephone: +46 (0)70 205 9620

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company’s patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

The information above was provided by Inhalation Sciences AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on August 5, 2019.



Dokument & länkar